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Appearance of tumor necrosis factor-a and soluble TNF-receptors I
and II in peritoneal effluent of CAPD. Dialysate and serum concentrations
of tumor necrosis factor-a (TNF-a), soluble TNF-receptor I (sTNFRI)
and soluble TNF-receptor II (sTNFRII) were measured during stable and
infectious CAPD to determine whether these mediators are released
intraperitoneally or derived from the circulation. Dialysate/serum ratios
were compared to those of various marker proteins for peritoneal
transport and to interleukin-6 (IL-6), which is locally produced. Peritoneal
immunoreactive TNF-a could be detected in 19 of 20 stable CAPD
patients after a night dwell, but only occasionally and in lower concentra-
tions during and after a standard four-hour peritoneal permeability test.
Both sTNFRs highly exceeded TNF-a dialysate concentrations. In case of
peritonitis a median 16-fold increase in dialysate TNF-a occurred on the
first day, which declined towards control values during a longitudinal
follow-up of eight consecutive days. sTNFRI and sTNFRII in dialysate
increased three- to fourfold. Their peaks, however, appeared on the
second peritonitis day. Bioactive TNF-cs was only detected when immu-
noreactive levels exceeded 1000 pg/mI. Serum values of all variables were
not altered during infection; sTNFRs exceeded TNF-a 300- to 400-fold.
During stable CAPD indirect evidence was obtained for transperitoneal
transport from plasma to dialysate of TNF-a (molecular wt 17 kD),
sTNFRI (55 kD) and sTNFRII (75 kD). Dialysate/serum (D/S) ratios were
higher, the lower the molecular weight; they were related to D/S ratios of
those marker proteins with the nearest molecular weight; DIS ratios were
unrelated to the intraperitoneally produced IL-6. Furthermore, the ob-
served D/S ratios were as expected theoretically for their molecular
weights. Higher than expected D/S ratios were found during peritonitis for
ThF-a on days 1 and 2, and for sTNFRII on day 2, pointing to local
release within the peritoneal cavity only in the acute inflammatory phase.
Gel permeation chromatography revealed that TNF-a was present in a
monomeric 17 kD form, unbound to receptors, whereas in case of
peritonitis smaller sTNFRII fragments, transported at a higher rate, could
not be excluded. Therefore, these higher than expected D/S ratios indicate
local production of TNF-a during peritonitis and possibly also of
sTNFRII, although transport of smaller receptor fragments might also
occur.
Inflammatory mediators have attracted much attention as nat-
ural constituents of host defense mechanisms over the last few
years [1—4]. Involvement of mediators in the context of peritoneal
dialysis is also reflected by the presence of these substances in the
peritoneal effluent. Some mediators are not merely transperito-
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neally transported from the circulation, but are produced locally
within the peritoneal cavity, even in the absence of overt clinical
infection. This has been demonstrated for the cytokines interleu-
kin-6 (IL-6) and IL-8, and for eicosanoids [5—10]. However,
preliminary reports on the presence and origin of the 17 kD
cytokine tumor necrosis factor-a (TNF-cs) have been concise and
conflicting [11, 12]. TNF-a is a central mediator involved in the
regulation of many biological responses. Apart from physiological
properties TNF-a might have deleterious effects when produced
excessively, since TNF-a is capable of inducing angiogenesis [13]
and fibroblast proliferation [14]. Therefore, intraperitoneal pro-
duction of this potentially harmful cytokine could theoretically
lead to structural changes of the peritoneal membrane and might
consequently affect the process of peritoneal dialysis.
Recently, two soluble TNF-receptors (sTNFR5) have been
described that are able to bind free TNF-a: sTNFRI (molecular
wt 55 kD) and sTNFRII (molecular wt 75 kD) [15]. These
receptors represent the extracellular domains of two TNF-recep-
tors that can be released from the cell surface by proteolytic
cleavage [16]. Binding to these shedded soluble receptors might
inactivate bioactive TNF-a and simultaneously reduce the sensi-
tivity of cells to TNF-a mediated effects. Alternatively, the
formation of such complexes might lead to a reservoir from which
bioactive TNF-a can be released [17]. Increased plasma concen-
trations of sTNFRs have been described in patients with end-stage
renal disease either before commencing renal replacement ther-
apy or during hemodialysis [18—2 1]. During peritoneal dialysis
serum proteins are transported from the circulation across the
peritoneal membrane to the peritoneal cavity. Based upon their
molecular weights, transperitoneal transport of sTNFRs would be
expected to occur at a rate similar to albumin (69 kD) and IgG
(150 kD). However, it is unknown whether these soluble receptors
are in fact present in peritoneal effluent and if so, whether they
appear in dialysate by peritoneal transport or are released locally
within the peritoneal cavity.
The present study was aimed first to establish the concentra-
tions of immunoreactive TNF-a, sTNFRI and sTNFRII in dialy-
sate and serum of patients treated with CAPD during stable and
infectious circumstances. This was accomplished in stable CAPD
patients both during a night dwell and during a standardized
four-hour peritoneal permeability test. The effect of inflammation
was established in a longitudinal study performed on eight
consecutive days from the start of peritonitis and once after
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Table 1. Patient characteristics of the studied patient groups
Group 1 2 3
N 20 7 12
M:F 10:10 5:2 8:4
Age years 56 (25—78) 55 (25—74) 49 (23—69)
CAPD duration 25 (3—98) 3 (2—35) 17 (4—107)
months
Peritonitis 0.5 (0—5.1) 1.4 (0—4) 2.1 (0—3.9)
incidence eplyr
Renal disease:
Diabetic 7 — 5
nephropathy
Chronic 3 2 2
glomerulonephritis
Chronic 1 — 2
interstitial
nephritis
Hypertensive 3 3 1
nephropathy
Adult polycystic 1 — 1
kidney
disease
Others and 5 2 1
unknown
Median values and ranges are given.
recovery. Bioactivity of peritoneal TNF-a was additionally studied
in stable and infectious CAPD patients. The second objective was
to investigate whether the presence of TNF-a and its sTNFRs in
dialysate merely reflects transperitoneal transport from the circu-
lation or local intraperitoneal release. Therefore, dialysate/serum
ratios of these substances were compared to dialysate/serum
ratios of marker proteins for peritoneal transport and to dialysate/
serum ratios of the intraperitoneally-produced 26 kD cytokine,
IL-6. These comparisons were made both in stable patients and in
patients with peritonitis. Finally, gel permeation chromatography
was performed on dialysate samples to assess the actual in vivo
molecular weights of TNF-a, sTNFRI and sTNFRII during
peritoneal dialysis.
Methods
Patients
In group 1 paired samples from night bags and serum (drawn
the next morning) were obtained from 20 clinically stable CAPD
patients. Patient characteristics are summarized in Table 1. Ten
patients used 2 liter exchanges, 10 used 1.5 liter. Glucose 3.86%
was employed by three patients, 2.27% by 5 and 1.36% by 12.
Dwell times ranged from 7.3 to 11.5 hours (median 10).
In a separate group of seven stable CAPD patients (group 2,
Table 1) TNF-a kinetics were studied during a standard four-hour
peritoneal permeability test with glucose 1.36% as described by us
previously [22]. Briefly, the peritoneal cavity was rinsed twice
before each study. Dialysate samples were taken 10 minutes after
instillation of the test bag, after one hour and after four hours.
Blood samples were drawn prior to each test. Four patients used
1.5 liter and three patients used 2 liter exchanges. All patients of
groups 1 and 2 were free of peritonitis at least three weeks prior
to the time of the study.
In group three 12 CAPD patients were studied during 15
episodes of peritonitis (Table 1). Nine patients used 2 liter
exchanges, and 3 used 1.5 liter exchanges. All were free to choose
their appropriate glucose concentration. Patients were followed
on eight consecutive days from the start of peritonitis and once
after recovery from the infection (control). Peritonitis was diag-
nosed when two of the following three criteria were present: (1)
dialysate leukocyte count exceeding 100 X 106/liter; (2) positive
dialysate culture; (3) abdominal complaints [23]. After delivery of
the first peritonitis bag to the hospital all subsequent night bags
were collected. These were weighed, samples were drawn and
stored immediately at —20°C. Serum samples were taken on day
1 and on the control day. All patients were treated initially with
oral and intraperitoneal cephradine during the first 24 hours as
described previously [24]. Briefly, patients received 125 mg/liter
intraperitoneally (loading dose 250 mg/liter) and 250 mg orally at
each dialysate exchange. Cephradine was continued orally after
the first 24 hours or replaced by another antibiotic if indicated by
the culture (8 cases). Antibiotics were continued for one week
after the dialysate leukocytes had dropped below 100 x 106/liter
and the culture had become negative. The control investigation
was performed 14 days after this time point. All patients re-
sponded well to the appropriate antibiotic treatment and CAPD
could be continued during and after peritonitis in all of them.
CAPD was performed in all patients with commercially avail-
able dialysate (Dianeal®, Baxter By, Utrecht, The Netherlands).
Informed consent was obtained from every patient after an
explanation of the purpose and methods of the study. The
protocol was approved by the committee of medical ethics of the
University Hospital of Amsterdam.
Measurements
All samples were kept frozen at —20°C until analysis. Cephra-
dine did not interfere with any of the performed determinations.
Immunoreactive TNF-a was measured in dialysate and serum
of all groups with a commercially available ELISA (Medgenix,
Brussels, Belgium) applying the instructions of the manufacturer.
This assay employs recombinant TNF-a with a molecular weight
of 17 kD. Addition of either recombinant soluble TNF-receptor I
or soluble TNF-receptor II in concentrations exceeding TNF-cr up
to 10-fold did not have any effect on the measurement of TNF-a.
This indicates that the employed ELISA detects both free TNF-a
and TNF-cs complexed with soluble TNF receptors. The lower
detection limit after dilution of the standard was 2 pg/ml. Intra-
assay variability was 7%, inter-assay variability 12%. Recovery of
exogenous TNF-a from peritoneal fluid was 108 14% (mean
SEM).
Bioactive TNF-a was determined in peritoneal effluents of
groups 1 (10 cases) and 3 (N = 6) using the murine fibrosarcoma
WEHI 164 cell line [25]. The detection limit was 0.1 U/ml,
corresponding with 1.6 pg/mI.
Soluble TNF-receptors were measured with a commercially
available ELISA (R&D Systems, Minneapolis, Minnesota, USA)
as recommended by the manufacturer. Briefly, 96-well polystyrene
microtiter plates, coated with a murine monoclonal antibody
against either sTNFRI or sTNFRII, were incubated with stan-
dards or diluted samples (using a mixture of diluents RD5 and
RD6K) for two hours at room temperature. This was followed by
three washing steps. Subsequently a polyclonal antibody against
sTNFRI or sTNFRII was added and incubated at room temper-
ature for two hours. After washing according to the instructions
substrate solution containing hydrogen peroxide was added and
incubated for 20 minutes. The color reaction was stopped with
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Fig. 1. Serum (A) and dialysate (B)
concentrations of immunoreactive TNF-q,
sTNFRJ and sTNFRII shown for each of the 20
stable CAPD patients studied after an overnight
dwell (group 1). The broken line indicates the
detection limit for TNF-a. TNF-a vs. sTNFRI
or sTNFRII, P  0.0001, both in dialysate
and in serum. sTNFRI vs. sTNFRII, P <
0.0001 in dialysate, P = 0.006 in serum.
sulfuric acid and the resulting color intensity was determined
spectrophotometrically at a wavelength of 450 nm ( EASIA
reader, Medgenix, Brussels, Belgium). Both assays for sTNFRs do
not cross-react with each other or with IL-la, IL-113, IL-2, IL-6,
IFN-y or TNF-a. The assays measure both free receptor and
receptor bound to TNF-a. The detection limit was 7.8 pg/mI for
both assays. Intra-assay variabilities were 4% for sTNFRI and 3%
for sTNFRII. Inter-assay variability was 8% for sTNFRI and 7%
for sTNFRII. Recoveries of exogenously added sTNFRs from
peritoneal dialysate were always above 70%.
IL-6 was measured in dialysate and serum of groups 1 and 3
using an ELISA as described by Helle et al [26] with only minor
modifications as previously reported by us [8]. The lower detec-
tion limit was 3 pglml. Intra-assay variability was 9%, inter-assay
variability was 14%.
Albumin, IgG and a2-macroglobulin were determined by im-
munonephelometry, using commercial antiserum (Dakopatts,
Glostrupp, Denmark). j3microglobulin was measured by EIA
(IMX, Abbott Diagnostics, Chicago, Illinois, USA). Coefficients
of variation for the determinations were 5% for 132-microglobulin
and 3% for albumin, IgG and a2-macroglobulin.
Gel permeation chromatography was performed on dialysate
and serum samples of both stable and infected CAPD patients
(days 1 and 2 of peritonitis) using a Superose 12 column with a
total volume of 25 ml (Pharmacia, Uppsala, Sweden). Samples
obtained during stable CAPD were concentrated tenfold. Gel
permeation was done at 0.4 mI/mm with sampling every minute.
Fractions of 0.4 ml were collected (pH 7.4). Phosphate buffered
saline served as eluent. Fractions were assayed for TNF-a and
sTNFRs as described above. Thyroglobulin, aldolase, chymotryp-
sin, ribonuclease and cytochrome C standards (all from Pharma-
cia) were used to calibrate the column, as well as recombinant
TNF-a (molecular wt 17 kD, Medgenix, Brussels, Belgium) and
the dialysate concentrations of IgG and albumin. The exponential
relationship between molecular weight and retention time yielded
the following equation: log molecular wt = 7.751 — 0.094 X
retention time. In addition serum samples from septic patients
with or without acute renal failure served as controls.
Calculations
Dialysate/serum ratios (DIS) were calculated for TNF-a and
sTNFRs (groups 1 and 3). These were compared to D/S ratios of
both marker proteins for peritoneal transport and the intraperi-
toneally produced 26 kD cytokine IL-6. Expected D/S ratios of
TNF-a and sTNFRs were determined assuming transperitoneal
transport from serum to dialysate. This was done by interpolation,
using the power relationship that exists between clearances or D/S
ratios of serum proteins and their molecular weights [27]. In these
calculations the molecular weights used in the stable patients
group and on the control day of group 3 were 17 kD for TNF-a,
55 lcD for sTNFRI and 75 kD for sTNFRII.
Statistics
Non-parametric tests were applied (Wilcoxon rank sum and
Spearman-rank correlation test). The differences between ob-
served and predicted D/S ratios of TNF-a and sTNFRs were
tested by a modified t-test. This test takes the variability of the
regression line between molecular weights and D/S ratios of
marker proteins into account.
Results
TNF-a and soluble TNF receptor concentrations
Stable CAPD. Dialysate and serum concentrations of immuno-
reactive TNF-a, sTNFRI and sTNFRII in 20 clinically stable
CAPD patients are shown in Figure 1 (group 1). Peritoneal
1'NF-a remained below the detection limit after an overnight
dwell only in one patient. In dialysate, TNF-a concentrations were
related with both sTNFRI and sTNFRII (r  0.71, P  0.003). In
serum TNF-a was only related to sTNFRII (r = 0.50, P = 0.03).
Dialysate TNF-a appeared biologically inactive in each patient (<
0.1 U/ml). TNF-a could not yet be detected in the dialysate of any
patient of group 2 in the samples obtained 10 minutes after the
start of a dwell, only in one patient after one hour (4 pg/mI) and
in three of the patients after four hours (2,4 and 5 pg/ml). In three
patients studied after both a short and a long dwell, peritoneal
TNF-a concentrations were higher in the night effluents than in
the four hour dwells. When group 1 and 2 were compared TNF-a
concentrations in dialysate were also significantly higher after an
overnight dwell (P < 0.001).
Peritonitis. Most episodes were caused by gram-positive micro-
organisms: Staphylococcus aureus (6 cases), Staphylococcus epider-
midis (3), Streptococcus sanguis (2), Streptococcus mitis (1) and
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Fig. 2. Median dialysate concentrations of TNF-a, sTNFRJ and sTNFRII in
15 episodes of peritonitis (group 3). Patients were followed on 8 consecutive
days from the start of the infection and once after recovery (control,
median day 22, range 19 to 35). Symbols are: (•) TNF-a; (A) sTNFRI;
(N) sTNFRII.
Streptococcus agalactiae (1). One infection was due to a gram-
negative bacterium (Acinetobacter). One culture remained nega-
tive, even after prolonged culture for seven days. Figure 2 shows
median dialysate concentrations of TNF-a, sTNFRI and sTNFRII
during the acute phase and the recovery from peritoneal infection.
TNF-a decreased from day 1 (median 82 pg/mI, range 12 to 1873
pg/mi) to the control day (5 pg/mi, range 2 to 23 pg/mi). In
contrast, peak dialysate concentrations of both sTNFRs were
observed on the second day (P 0.01 vs. TNF-a). Median
sTNFRI declined from 3113 pg/mi (range 1617 to 8367 pg/mi) on
day 2 to 1196 pg/ml (526 to 2460 pg/mi) after recovery (P <
0.001); sTNFRII decreased from 3270 pg/mi (1307 to 23225
pg/ml) to 854 pg/mI (257 to 2232 pg/mi) (P < 0.001). Bioactivity of
peritoneal TNF-a was determined on days 1 and 2 of peritonitis.
Only in two samples with immunoreactive TNF-a levels exceeding
1000 pg/mI was low bioactivity detected, that could be blocked by
anti-TNF-a. Serum concentrations measured during the acute
inflammatory phase were neither different from those measured
after recovery, nor from those observed in the stable patients of
group 1 (Table 2). All three mediators were however higher than
values reported for healthy individuals by the manufacturers of
the applied assays. No correlation was present between dialysate
TNF-a and sTNFRs on the first peritonitis day. On the control
day peritoneal TNF-n was related to sTNFRII (r = 0.73, P =
0.006), not to sTNFRI (r = 0.42, P = 0.12). Similar to the stable
patients of group 1, serum TNF-a after recovery was only related
to sTNFRII (r = 0.61, P = 0.02).
Transperitoneal transport versus local production
Stable CAPD. Figure 3 shows D/S ratios of TNF-a and sTNFRs
for each individual of group 1. All D/S ratios were lower than 1.0.
Also, the D/S ratios were higher the lower the molecular weight,
suggesting size-selective peritoneal transport rather than local
synthesis. Table 3 summarizes these data in relation to D/S ratios
of marker proteins for peritoneal transport and to D/S ratios of
Table 2. Serum concentrations (pg/mI) of TNF-a, sTNFRI and
sTNFRII
Stable CAPD
Peritonitis
Day 1 After recovery
TNF-a 64
(33—59)
59
(37—84)
53
(33—93)
sTNFRI 22200
(10316—32720)
17986
(9948—34220)
18041
(5786—38520)
sTNFRII 25020
(12860 —38540)
23800
(14320—37980)
19020
(10160—45 150)
Median values and ranges are given during stable CAPD (N = 20,group
1) and during the acute phase and recovery from peritonitis (N = 15,
group 3).
the intraperitoneally produced IL-6. In contrast to IL-6 (26 kD),
D/S ratios of TNF-a and sTNFRs were in the range as expected
for transport of solutes with these molecular weights. Rank
correlations were found for D/SThF, D/SSTNFRI and D/SSThFRII
with D/S ratios of marker proteins. The best correlations are
shown in Figure 4. In contrast, D/STNF., D/SSTNFRI or D/SSThFRII
were not related to D/S1L6 (Fig. 4). D/SIL6 appeared also
unrelated to any of the marker proteins. D/STN. correlated with
D/S ratios of both sTNFRs (r  0.83, P 0.002); D/SSTNFRI was
related to D/SSTNFRIJ (r = 0.97, P < 0.001).
The linear relationship that exists between D/S ratios of marker
proteins for peritoneal transport and their molecular weights
when plotted on a double logarithmic scale is given in Figure 5.
During stable dialysis the observed D/SSTNFRII was similar to the
predicted value for transport of a globular protein with a molec-
ular weight of 75 kD (upper left panel). For TNF-a and sTNFRI
the observed D/S ratios seemed to be higher than expected, since
they appeared above the line for transperitoneal transport. How-
ever, the difference was not statistically significant. Thus, both
TNF-a and sTNFRs are probably transported from the circulation
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Fig. 3. Dialysate/serum (D/S) ratios for TNF-a (17 kD), STNFRJ (55 kD)
and sTNFRII (75 kD) during stable CAPD (group 1). P  0.0002 for all
differences between all variables.
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Table 3. D/S ratios of TNF-a and sTNFRs in relation to DIS ratios of marker proteins for peritoneal transport and the locally produced
cytokine IL-6
Molecular
wt
D/S ratio
Stable CAPD
Peritonitis
Day 1 Day 2 After recovery
132-microglobulin 11.8 0.264
(0.128—0.588)
0.224
(0.111—0.727)
0.354
(0.236—0.612)
0.245
(0.138—0.423)
TNF-a 17 0.218
(0—0.610)
1.455
(0.233—27.544)
0.413
(0.107—4.791)
0.100
(0.033—0.277)
sTNFRI 55 0.062
(0.032—0.242)
0.084
(0.031—0.222)
0.157
(0.078—0.370)
0.066
(0.028—0.110)
albumin 69 0.024
(0.014—0.070)
0.032
(0.011—0.101)
0.054
(0.032—0.075)
0.029
(0.013—0,047)
sTNFRII 75 0.034
(0.009—0.113)
0.051
(0.012—0.195)
0.117
(0.051—1.749)
0.036
(0.007—0.072)
IgG 150 0.015
(0.006—0.042)
0.022
(0.008—0.059)
0.029
(0.016—0.038)
0.016
(0.007—0.026)
a2-macroglobulin
IL-6
820
26
0.003
(0.001—0.030)
26
(0—57)
0.009
(0.001—0.028)
2519
(2—15500)
0.012
(0.004—0.030)
526
(48 —12473)
0.004
(0.001—0.010)9
(0.5—65)
Median values and ranges are given during stable CAPD (N = 20, group 1) and during the acute phase of and after recovery from peritonitis (N =
15, group 3).
Fig. 4. Spearman rank cotrelations between
D/S ratios of TNF-a (17 kD), sTNFRJ (55 kD)
and sTNFRII (75 kD) with marker proteins for
peritoneal transport with a similar molecular
weight. No correlation was present with the
intraperitoneally produced 26 kD cytokine
IL-6 (shown for TNF.a in B). A. P = 0.002,
r = 0.721. B. r = 0.078, NS, C. P = 0.001,
r = 0.924. D. P = 0.0001, r 0.908.
across the peritoneal membrane to dialysate during stable dialysis,
similar to marker proteins for peritoneal transport.
Peritonitis. Table 3 sunmarizes the DIS ratios of TNF-a,
sTNFRI and sTNFRII during the first two days of peritonitis and
after recovery (group 3). The observed D/S ratios during these
days are plotted relative to the expected values based upon
transperitoneal transport in Figure 5. The observed D/STNFa was
significantly higher than predicted on the first two days of the
infection (P < 0.001, Fig. 5, upper and lower right panels). On the
second day of peritonitis the observed D/S ratio of sTNFRII was
also significantly higher than expected for transport of a 75 kD
solute (P < 0.02). The lower left panel shows that all DIS ratios
were within the expected range after recovery from peritonitis,
similar to the stable patients of group 1.
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Gel permeation chromatography. To examine whether molecular
sizes of TNF-a and sTNFRs were different during peritoneal
infection, dialysate samples obtained during peritonitis were
analyzed by gel permeation chromatography and compared to
concentrated dialysate derived from stable CAPD patients (Fig.
6). The TNF-a peak in dialysate eluted in the same fraction as
recombinant monomeric TNF-a (17 kD) or TNF-a in serum from
septic patients, irrespective whether the dialysate was obtained
during peritonitis or stable CAPD. TNF-cs did not elute as a single
sharp peak during stable CAPD. A single sTNFRI peak was
observed both during peritonitis and stable dialysis, corresponding
with a molecular weight of —69 kD. However, for sTNFRII
multiple peaks were observed during stable CAPD (——69 and 106
kD), on the first peritonitis day (—45, 69 and 106 kD) and on the
second peritonitis day (—-—55 and 106 kD).
Discussion
Immunoreactive TNF-a could be detected in nearly all dialy-
sates after an overnight dwell, but only occasionally and in lower
concentrations during and after a standard four-hour peritoneal
permeability test. In case of peritoneal infection a median 16-fold
increment occurred for TNF-a on the first day, whereas three- to
fourfold increases of sTNFRs were found on the second day of
peritonitis, significantly later than TNF-cs. Soluble TNF-receptors
markedly exceeded TNF-a under all circumstances, both in
dialysate and in the circulation.
Serum concentrations of all three agents were considerably
higher than those described for healthy individuals. Similar ele-
vated values have been found in uremic patients before or during
treatment with hemo- or peritoneal dialysis by other groups
[18—21, 28, 29]. These high concentrations are probably related to
the presence of chronic renal failure, which leads to either a
decreased clearance or an increased release of these substances.
Indeed, an inverse relationship has been described between serum
soluble TNF-receptors and renal function [19, 30]. Some caution,
however, is warranted concerning the interpretation of increased
TNF-a levels, since TNF-a binding proteins—like soluble recep-
tors—can interfere with the measurement of TNF-a in biological
fluids. For example, Haran et al could no longer detect differences
in serum TNF-a concentrations between hemodialysis patients
and healthy controls, when a modified assay was used [31]. The
TNF-c assay used in the present study detects TNF-a both in its
free and receptor-bound form. As will be discussed below, our
data indicate TNF-a was present in dialysate mainly in a free
form.
Peritoneal infection did not affect serum concentrations of
TNF-a, sTNFRI or sTNFRII. This has been reported for TNF-cr
before [32] and underlines that CAPD-related peritonitis reflects
a local inflammatory process. In contrast to serum, dialysate
concentrations of TNF-a and sTNFRs were increased in the acute
inflammatory phase. It is not unexpected that peak dialysate
concentrations of sTNFRs occurred after the TNF-a peak. TNF-a
is a proximal mediator, able to induce release of other substances,
including its own receptors [331. A similar time course has been
shown for serum concentrations of human volunteers with exper-
imental endotoxemia [34]. These in vivo studies indicate that
TNF-a probably regulates its own activity.
As might be expected, given the excess of soluble TNF-
receptors, bioactivity of peritoneal TNF-a could only be detected
when TNF-a was present in very high concentrations during
peritonitis. This seems contradictory to another study [32], that
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Fig. 6. Representative patterns of gel chromatography of TNF-a, sTNFRJ and sTNFRtlperformed in dijf erent situations. IgG (150 kD) and albumin (67 kD)
were used as molecular weight standards. A. Elution profile of the applied control samples for TNF-a: * recombinant monomeric TNF-a (17 kD); —e—
serum from septic patient with normal kidney function; —e— serum from septic patient with acute renal failure. B. Elution profile during the first
peritonitis day. C. Elution profile of dialysate from stable CAPD patient. D. Elution profile on the second peritonitis day. Symbols are: (•) TNF-a; (A)
sTNFRI; (•) sTNFRII.
reported bioactive TNF-a both in stable and infectious circum-
stances. The discrepancy is possibly due to the use of different cell
lines to determine bioactivity. In addition, these authors reported
similar peritoneal TNF-a concentrations during stable CAPD and
peritonitis. However, they compared long, uninfected night dwells
to shorter peritonitis dwells. Since more TNF-a accumulates
intraperitoneally, the longer the dwell time, increased TNF-a
concentrations during infection might have remained unnoticed.
In case of stable CAPD transperitoneal transport of TNF-a and
sTNFRs was indicated, rather than intraperitoneal release. First,
DIS ratios were higher, the lower the molecular weight of the
substance, consistent with size selective transport from blood to
dialysate [27]. Secondly, their DIS ratios were in the range
between those of marker proteins for peritoneal transport with a
molecular weight approaching that of TNF-a, sTNFRI or
sTNFRII. Thirdly, the strongest correlations were found for DIS
ratios between TNF-a and /32-microglobulin (11,8 kD), sTNFRI
and albumin (69 kD) and sTNFRII and IgG (150 kD). Fourthly,
the D/S ratios of these mediators were unrelated to that of IL-6,
a locally produced 26 kD cytokine. Finally, the observed in vivo
D/S ratios of TNF-cs, sTNFRI and sTNFRII were consistent with
predicted values for transperitoneal transport of 17 kD, 55 lcD and
75 kD solutes, respectively. Our data on TNF-a are in agreement
with those from Ham et al [11], who also suggested transperito-
neal transport, but contradict data from Floege et al [12] and
Mariano et a! [32]. However, they did not compare D/S ratios of
TNF-a to those of marker proteins for transport and locally
released solutes.
In case of acute peritonitis significantly higher DIS ratios than
theoretically expected for their molecular sizes were observed for
TNF-a and sTNFRII. This can be explained either by intraperi-
toneal release or by the presence of smaller fragments, that will be
transported at a higher rate than the full size solutes. Gel
permeation chromatography was therefore performed on dialy-
sate to distinguish between these possibilities. TNF-a always
eluted in the same fraction as recombinant monomeric TNF-a,
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irrespective whether infection was present or not. It implies that
TNF-a was constantly present in a monomeric 17 kD form.
Interestingly, both soluble receptors eluted in fractions distinct
from TNF-a. These data therefore indicate intraperitoneal re-
lease of free, monomeric 17 kD TNF-a during acute peritonitis,
unbound to soluble receptors. This would be consistent with our
inability to detect bioactive TNF-a in most dialysate samples; only
trimeric TNF-a is considered to be biologically active [35]. In
dialysate obtained during stable CAPD did TNF-a not elute as a
single sharp peak. This was potentially caused by the tenfold
concentration step that was necessary to obtain sufficient TNF-a
from dialysate samples of stable patients to perform chromatog-
raphy. Alternatively, low concentrations of dimeric or trimeric
TNF-a might have been present. In contrast to TNF-a, the
existence of smaller fragments of sTNFRII in peritoneal fluid
could not be excluded. Thus, in addition to local sTNFRII release
during acute peritonitis, diffusion of smaller fragments, that were
transported at a higher rate than the entire 75 kD receptor, could
have occurred.
The low dialysate TNF-a concentrations during stable CAPD,
which were biologically inactive, do not suggest unfavorable
effects on the maintenance of peritoneal membrane function in
terms of fibrosis or angiogenesis. These dialysate concentrations
do not indicate that the instillation of commercially available
dialysis solutions leads to local release of TNF-cv. It implies that
dialysate TNF-a concentrations are not useful for the establish-
ment of improved biocompatibility when new dialysis fluids are
tested. In case the instillation of a new fluid would lead to a
marked rise in TNF-a concentrations, such a fluid would be very
bioincompatible. Although TNF-a was produced locally during
peritonitis, this occurred only in the acute phase; peritoneal
concentrations became normal within one week. Furthermore,
soluble TNF-receptors increased as well, probably to regulate
TNF-a activity. In case of infection synthesis of TNF-a very likely
reflects a physiological response to infectious agents. Endogenous
TNF-a is, for example, required in vivo in mice for survival of
otherwise lethal peritonitis [36]. Peritoneal macrophages, which
form the first line of defense within the peritoneal cavity, are a
likely source of TNF-a [37]. These cells are involved in a cytokine
network with mesothelial cells, which line the entire cavity and are
capable of releasing inflammatory mediators like IL-6, IL-8 and
eicosanoids [38—40], and possibly also with fibroblasts and neu-
trophils [41]. It is not currently known which of the resident
peritoneal cells express soluble TNF-receptors. Nevertheless, it is
tempting to speculate that upon bacterial challenge macrophages
release the proinflammatory cytokine TNF-a. TNF-a might sub-
sequently activate other peritoneal cells for additional TNF-a
release and shedding of sTNFRII.
It is concluded that TNF-a and its soluble TNF-receptors
appear in dialysate of stable CAPD patients by transperitoneal
transport from the circulation. Local intraperitoneal release prob-
ably occurs for TNF-a and sTNFRII only in case of acute
peritoneal infection.
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